Reading the DNA Fingerprints of Prostate Cancer

/in /by

Prostate cancer does not develop in the same way in every patient. Different biological processes can damage the DNA of cancer cells, leaving behind characteristic patterns, or “mutational signatures.” A recent study, published on Nature, used whole-genome sequencing to combine these patterns and identify eight integrated mutational footprints (IMFs), providing a broader picture of how […]

Read more

Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC

/in , , , /by

Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]

Read more

STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer

/in , , , , /by

A multicentre, randomised trial published in The Lancet Oncology shows that a supervised, behaviourally supported lifestyle programme can measurably blunt the adverse effects of androgen deprivation therapy (ADT) for prostate cancer. Called STAMINA, the study enrolled 700 men on ADT across 15 NHS trusts in England and randomly assigned them in a 5:4 ratio to […]

Read more

Dietary Fat and Survival After Nonmetastatic Prostate Cancer

/in /by

A new cohort study published in JAMA Network provides some of the most detailed evidence to date on how the type of fat men eat after a prostate cancer diagnosis relates to long-term survival. The analysis, based on 4,884 participants in the Health Professionals Follow-Up Study followed for a median of 12.8 years, shows that […]

Read more

Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer

/in , , /by

IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]

Read more

De‑escalation therapy in metastatic prostate cancer: can some men safely stop ADT + ARPI after a deep response?

/in /by

For men with metastatic prostate cancer, the current standard is continuous androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach improves survival but comes with substantial clinical and financial toxicity: fatigue, metabolic changes, sexual dysfunction, bone loss, cardiovascular risk, and long‑term treatment costs. The […]

Read more

Phase 3 Trial Tests a New B7-H3 Strategy in Advanced Prostate Cancer

/in , , /by

A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]

Read more

How Radium‑223 Plus Enzalutamide Accelerates ALP and PSA Responses in Bone‑Metastatic mCRPC

/in /by

An exploratory post hoc analysis of the international PEACE‑3 trial adds a compelling biomarker layer to the already positive story of combining radium‑223 with enzalutamide in men with bone‑metastatic, castration‑resistant prostate cancer. The parent study, a phase 3 randomised trial in asymptomatic or mildly symptomatic metastatic castration‑resistant prostate cancer (mCRPC) with bone metastases, had already […]

Read more